Clinical significance of CHD1L in hepatocellular carcinoma and therapeutic potentials of virus-mediated CHD1L depletion

Gut

Volumn 60, Issue 4, 2011, Pages 534-543

  Chen, Leilei ^a,b,c   Yuan, Yun Fei ^a   Li, Yan ^a   Chan, Tim Hon Man ^b,c   Zheng, Bo Jian ^b   Huang, Jun ^a   Guan, Xin Yuan ^a,b,c  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c THE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CISPLATIN; DOXORUBICIN; FLUOROURACIL; IODINATED POPPYSEED OIL; NUCLEAR RECEPTOR NUR77; SHORT HAIRPIN RNA;

ADENOVIRUS; ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CARCINOGENESIS; CARCINOGENICITY; CELL SURVIVAL; CHD1L ONCOGENE; CHEMOEMBOLIZATION; CLINICAL EVALUATION; CLINICAL FEATURE; CLONOGENESIS; COHORT ANALYSIS; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; GENE FUNCTION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; THERAPY RESISTANCE; TREATMENT RESPONSE; TUMOR VOLUME; TUMOR XENOGRAFT;

ADENOVIRIDAE; ADULT; AGED; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; DNA HELICASES; DNA-BINDING PROTEINS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; GENE SILENCING; GENE THERAPY; GENETIC VECTORS; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; RETROSPECTIVE STUDIES; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS; YOUNG ADULT;

EID: 79952532633     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2010.224071     Document Type: Article

References (30)

1. McGlynn KA, Tarone RE, El-Serag HB. A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States. Cancer Epidemiol Biomarkers Prev 2006;15:1198-203.
2. Yeo W, Mok TS, Zee B, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005;97:1532-8. (Pubitemid 41631953)
3. Greten TF, Papendorf F, Bleck JS, et al. Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. Br J Cancer 2005;92:1862-8. (Pubitemid 40826134)
4. Blandino G, Levine AJ, Oren M. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 1999;18:477-85. (Pubitemid 29060623)
5. Moll UM, Marchenko N, Zhang XK. p53 and Nur77/TR3-transcription factors that directly target mitochondria for cell death induction. Oncogene 2006;25:4725-43. (Pubitemid 44187622)
6. Nerenstone SR, Ihde DC, Friedman MA. Clinical trials in primary hepatocellular carcinoma: current status and future directions. Cancer Treat Rev 1988;15:1-31.
7. Guan XY, Fang Y, Sham JS, et al. Recurrent chromosome alterations in hepatocellular carcinoma detected by comparative genomic hybridization. Genes Chromosomes Cancer 2000;29:110-16.
8. Marchio A, Meddeb M, Pineau P, et al. Recurrent chromosomal abnormalities in hepatocellular carcinoma detected by comparative genomic hybridization. Genes Chromosomes Cancer 1997;18:59-65. (Pubitemid 27020257)
9. Wong N, Lai P, Lee SW, et al. Assessment of genetic changes in hepatocellular carcinoma by comparative genomic hybridization analysis: relationship to disease stage, tumor size, and cirrhosis. Am J Pathol 1999;154:37-43. (Pubitemid 29031609)
10. Ma NF, Hu L, Fung JM, et al. Isolation and characterization of a novel oncogene, amplified in liver cancer 1, within a commonly amplified region at 1q21 in hepatocellular carcinoma. Hepatology 2008;47:503-10. (Pubitemid 351280718)
11. Chen M, Huang JD, Hu L, et al. Transgenic CHD1L expression in mouse induces spontaneous tumors. PLoS One 2009;4:e6727.
12. Chen L, Hu L, Chan TH, et al. Chromodomain helicase/adenosine triphosphatase DNA binding protein 1-like (CHD1l) gene suppresses the nucleus-to-mitochondria translocation of nur77 to sustain hepatocellular carcinoma cell survival. Hepatology 2009;50:122-9.
13. Chen L, Chan TH, Yuan YF, et al. CHD1L promotes hepatocellular carcinoma progression and metastasis in mice and is associated with these processes in human patients. J Clin Invest 2010;120:1178-91.
14. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
15. Ng IO, Srivastava G, Chung LP, et al. Overexpression and point mutations of p53 tumor suppressor gene in hepatocellular carcinomas in Hong Kong Chinese people. Cancer 1994;74:30-7. (Pubitemid 24187606)
16. Bruix J, Boix L, Sala M, et al. Focus on hepatocellular carcinoma. Cancer Cell 2004;5:215-19. (Pubitemid 38402113)
17. Curley SA, Izzo F, Ellis LM, et al. Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg 2000;232:381-91.
18. Hemming AW, Cattral MS, Reed AI, et al. Liver transplantation for hepatocellular carcinoma. Ann Surg 2001;233:652-9. (Pubitemid 32378649)
19. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36. (Pubitemid 43112690)
20. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-9. (Pubitemid 34607087)
21. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164-71. (Pubitemid 34454013)
22. Boucher E, Corbinais S, Brissot P, et al. Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen). Cancer Chemother Pharmacol 2002;50:305-8.
23. Colombo M, Sangiovanni A. The European approach to hepatocellular carcinoma. Hepatogastroenterology 2002;49:12-16. (Pubitemid 34289478)
24. Wang Y, Wu MC, Sham JS, et al. Prognostic significance of c-myc and AIB1 amplification in hepatocellular carcinoma. A broad survey using high-throughput tissue microarray. Cancer 2002;95:2346-52.
25. Stuart K, Tessitore J, Huberman M. 5-Fluorouracil and alpha-interferon in hepatocellular carcinoma. Am J Clin Oncol 1996;19:136-9.
26. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002;296:550-3. (Pubitemid 34408678)
27. Dai Y, Qiao L, Chan KW, et al. Adenovirus-mediated down-regulation of X-linked inhibitor of apoptosis protein inhibits colon cancer. Mol Cancer Ther 2009;8:2762-70.
28. Carette JE, Overmeer RM, Schagen FH, et al. Conditionally replicating adenoviruses expressing short hairpin RNAs silence the expression of a target gene in cancer cells. Cancer Res 2004;64:2663-7. (Pubitemid 38500597)
29. Connolly K, Mitter R, Muir M, et al. Stable XIAP knockdown clones of HCT116 colon cancer cells are more sensitive to TRAIL, taxanes and irradiation in vitro. Cancer Chemother Pharmacol 2009;64:307-16.
30. Inoue H, Shiraki K, Murata K, et al. Adenoviral-mediated transfer of p53 gene enhances TRAIL-induced apoptosis in human hepatocellular carcinoma cells. Int J Mol Med 2004;14:271-5.